Please assess the completion status of the following clinical trial:

Trial Title: Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be between 18 years and 65 years of age~* WHO Class II-III~* Diagnosis of one of the following Group I WHO clinical classifications: Idiopathic or familial pulmonary arterial hypertension (PAH) or PAH associated with a collagen vascular disease or PAH associated with congenital systemic-to-pulmonary shunt repaired greater than 5 years prior to study entry or PAH associated with portal hypertension with mild or moderate hepatic dysfunction or PAH associated with drugs or toxins.~* Receiving inhaled iloprost for at least two months prior to screening or prior to treatment discontinuation.~* May have discontinued iloprost treatment against medical advice up to thirty days prior to screening~* Be mentally and physically capable of learning to administer Remodulin using an intravenous infusion pump.~Exclusion Criteria:~* Be a nursing or pregnant woman~* Have any PAH medication, other than inhaled iloprost, discontinued within the week prior to study entry.~* Received any prostacyclin or prostacyclin analog except iloprost in the past 3 months.~* Previous history of significant parenchymal lung disease~* Have any other type of PAH including but not limited to PAH related to thrombotic or embolic disease~* Have evidence of left-sided heart disease~* Musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease, which is thought to limit ambulation, or be connected to a machine, which is not portable.~* Uncontrolled systemic hypertension or chronic renal insufficiency~* Use of an investigational drug within the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).